Skip to main content
padlock icon - secure page this page is secure

Gold Nanocrystals with Well-Defined Crystallographic {111} Facets Suppress Pathological Neovascularization

Buy Article:

$106.51 + tax (Refund Policy)

Vascular endothelial growth factor (VEGF) is a main factor in pathological neovascularization in various human diseases including age-related macular degeneration, cancer, and diabetic complications. Interestingly, gold nanospheres are known to bind to VEGF and to suppress VEGF-mediated angiogenesis. The anti-angiogenic effects are known to be governed by the size and surface charge of the nanoparticles. However, studies on the role of the shape in biological actions are limited. In this study, we investigate the anti-angiogenic properties of nanocrystals that have well-defined crystallographic {111} facets. Single-crystalline icosahedral and octahedral gold nanocrystals effectively scavenge VEGF just as nanospheres with similar diameter. In addition, they suppress the in vitro VEGF-induced activation of the VEGF receptor and the proliferation of endothelial cells. They also significantly inhibit in vivo VEGF-mediated retinal vascular permeability. These results thus suggest that gold nanocrystals with {111} facets can provide a useful platform for nanoparticle-based treatment of VEGF-driven pathological neovascularization beyond their current optical and catalytic applications.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: July 1, 2016

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more